INO
Inovio Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
INO fundamentals
Inovio Pharmaceuticals (INO) released its earnings on Mar 12, 2026: revenue was 0 (YoY -100.00%), met estimates; EPS was -0.26 (YoY +60.00%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.26
+60.00%
Report date
Mar 12, 2026
INO Earnings Call Summary for Q4,2025
- FDA Milestone Progress: INO-3107 BLA under accelerated review with PDUFA date October 2026; awaiting FDA meeting to resolve eligibility concerns.
- Clinical Efficacy: 72% of patients saw 50%-100% surgery reduction in first year, improving to 86% by year two, with no surgery requirement during treatment.
- Financial Sustainability: $58.5M cash on hand, extended runway to Q4 2026, and 23% reduction in annual operational expenses.
- Commercial Readiness: Finalizing partnerships and go-to-market strategy for rapid launch, leveraging RRP Foundation's first-line immunotherapy endorsement.
- Pipeline Expansion: Exploring partnerships for DPROT and dMAb programs while advancing late-stage candidates like INO-3112 post-approval.
EPS
Actual | -3.12 | -9.96 | 1.32 | -1.68 | -3.24 | -4.68 | -3.48 | -6 | -4.32 | -5.52 | -1.8 | -2.64 | -1.92 | -1.56 | -1.56 | -1.1 | -1.31 | -1.19 | -0.89 | -0.65 | -0.51 | -0.61 | -0.87 | -0.26 | |||||||||||
Forecast | -2.66 | -1.98 | -2.22 | -2.565 | -2.235 | -2.988 | -3.876 | -3.7867 | -4.128 | -3.72 | -3.4971 | -2.016 | -1.74 | -1.74 | -1.52 | -1.186 | -1.0133 | -1.1017 | -1.15 | -0.8369 | -0.692 | -0.61 | -0.4217 | -0.358 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -17.29% | -403.03% | +159.46% | +34.50% | -44.97% | -56.63% | +10.22% | -58.45% | -4.65% | -48.39% | +48.53% | -30.95% | -10.34% | +10.34% | -2.63% | +7.25% | -29.28% | -8.01% | +22.61% | +22.33% | +26.30% | 0.00% | -106.31% | +27.37% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.33M | 267.19K | 236.18K | 5.60M | 371.12K | 272.82K | 291.70K | 839.00K | 199.07K | 784.39K | 9.20M | 125.00K | 114.94K | 225.97K | 388.45K | 103.00K | 0 | 100.76K | 0 | 117.00K | 65.34K | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.91M | 2.61M | 3.05M | 1.22M | 1.06M | 1.09M | 873.60K | 2.52M | 773.00K | 529.00K | 623.17K | 339.28K | 275.00K | 275.00K | 116.67K | 360.00K | 158.33K | 134.00K | 112.83K | 40.00K | 12.50K | 10.00K | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -30.60% | -89.75% | -92.25% | +359.00% | -65.01% | -74.99% | -66.61% | -66.73% | -74.25% | +48.28% | +1376.33% | -63.16% | -58.20% | -17.83% | +232.95% | -71.39% | -100.00% | -24.80% | -100.00% | +192.50% | +422.74% | -100.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What were the key takeaways from Inovio Pharmaceuticals's earnings call?What is the revenue and EPS growth rate for Inovio Pharmaceuticals year over year?What does Inovio Pharmaceuticals do and what are its main business segments?What factors drove the changes in Inovio Pharmaceuticals's revenue and profit?What is the market's earnings forecast for Inovio Pharmaceuticals next quarter?Did Inovio Pharmaceuticals beat or miss consensus estimates last quarter?What is Inovio Pharmaceuticals's latest dividend and current dividend yield?What guidance did Inovio Pharmaceuticals's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
